JPS61167622A - Diabetes-controlling agent - Google Patents

Diabetes-controlling agent

Info

Publication number
JPS61167622A
JPS61167622A JP60010264A JP1026485A JPS61167622A JP S61167622 A JPS61167622 A JP S61167622A JP 60010264 A JP60010264 A JP 60010264A JP 1026485 A JP1026485 A JP 1026485A JP S61167622 A JPS61167622 A JP S61167622A
Authority
JP
Japan
Prior art keywords
diabetes
beer yeast
cell wall
beer
fiber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP60010264A
Other languages
Japanese (ja)
Inventor
Yoshiatsu Akazawa
赤澤 好温
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Breweries Ltd
Original Assignee
Asahi Breweries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Breweries Ltd filed Critical Asahi Breweries Ltd
Priority to JP60010264A priority Critical patent/JPS61167622A/en
Publication of JPS61167622A publication Critical patent/JPS61167622A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PURPOSE:To use cell wall component of beer yeast as a diabetes-controlling agent containing a large amount of food fiber. CONSTITUTION:It has ben found that the cell wall of beer yeast is rich in vitamins and minerals, contains 25% crude protein and 50.4% food fiber such as glucan, mannan, etc., and is effective as a fiber diet for controlling diabetes. The beeryeast cell wall is obtained by contacting fresh beer yeast produced by Asahi Beer Co, with a sodium hydroxide solution of 10pH for 50sec to remove the bitter taste, washing with water, letting stand at 50-70 deg.C for >=2hr to effect the autodigestion, and extracting and removing the solubilized component with water. The obtained powder is tableted to a tablet of 243.75mg weight. Daily administration of 30 tablets of the beer yeast corresponds to about 3.5g of food fiber. Improvement in GTT, in renal function such as lowering of HbA value, and hyperlipemia accompanied by diabetes has been confirmed.

Description

【発明の詳細な説明】 ビール酵母には、蛋白質、ビタミン類(BIBよ、Bい
B。、ニコチン酸、パントテン酸などのビタミンB群及
びプロビタミンB等)、ミネラル(P、に、Fe、Mg
、Ca等)、RNA等の核酸関連物質等の薬用成分が多
く含まれているので古くから広範囲の疾病の予防と治療
に、又代謝機能の促進、栄養強化などとして利用されて
いる。ただビール酵母で生ずる余剰ビール酵母にはホッ
プに由来する苦味があり、且つ細胞質には強い自己消化
性があるため、生酵母を短時間PH9〜11のアルカリ
水溶液と接触させ洗浄し、脱苦味し、脱苦味後に乾燥さ
せて自己消化性を失なわせることを必須の工程とじてい
る。そしてこの急速乾燥による細胞質の自己消化の防止
は、酵母の有用成分が多く細胞室内に存在すると考えら
れていたので、成分の自己消化による分解によって有用
成分が減少するのを防止しようとするためでありこの考
え方向体に誤りがあるわけではない。しかし酵母の構成
成分の半ばを占める細胞壁成分の組成や薬理作用におい
ては余り考慮されなかったことも事実である。
[Detailed description of the invention] Brewer's yeast contains proteins, vitamins (BIB, B vitamins such as nicotinic acid, pantothenic acid, and provitamin B), minerals (P, Fe, Mg
Since it contains many medicinal ingredients such as nucleic acid-related substances such as RNA, etc.), it has been used for a long time for the prevention and treatment of a wide range of diseases, as well as for promoting metabolic function and fortifying nutrition. However, surplus brewer's yeast produced by brewer's yeast has a bitter taste derived from hops, and the cytoplasm has strong autolytic properties, so raw yeast is washed by contacting it with an alkaline aqueous solution with a pH of 9 to 11 for a short time to remove bitterness. After removing bitterness, the essential step is to dry it to lose its self-digestion properties. This rapid drying prevents autolysis of the cytoplasm, as it was thought that many of the useful components of yeast exist within the cell chambers, to prevent useful components from decreasing due to decomposition due to autolysis. There is nothing wrong with this way of thinking. However, it is a fact that little consideration has been given to the composition and pharmacological effects of cell wall components, which make up half of the yeast components.

一方食物繊維が糖尿病のコントロールに役立つ事が判り
、糖尿病のコントロール食として繊維素が用いられるよ
うになったが、知られている繊維素には栄養素の不足す
るものや偏よりのある食品が多くこの点満足すべきもの
は殆どみられなかった。
On the other hand, it has been discovered that dietary fiber is useful for controlling diabetes, and fiber has come to be used as a diabetes control food, but many of the known fibers lack nutrients or are unbalanced. There was hardly anything that was satisfactory in this respect.

本発明者はビール酵母の細胞壁画分が50.4%量の食
物繊維を含んでいることを突きとめ本発明に到達した。
The present inventors discovered that the cell wall fraction of brewer's yeast contains 50.4% dietary fiber and arrived at the present invention.

(以下余白) ビール酵母細胞壁分画の一般成分(分析例)乾燥減量 
        10.9%強熱残分        
 1.5% 全窒素          4.0% 粗蛋白質(N X 6.25)     25.0%チ
アミン塩      10μg/g>リボフラビン  
    10μg/g>全リン          0
.4% 全還元糖         49.5%・グリコーゲン
       2469%・・グルカン       
   14.8%*傘マンナン          1
3.9%傘傘拳グリコース換算 (塩酸分解後ソモギー法による) ・申分爾後アンスロン法による そして本発明者はビール酵母細胞壁の粉末を錠剤化し糖
尿病コントロール繊維素として試用し、糖尿病患者の血
糖、血中インスリン、脂質に対する影響について検討し
たことにより予期以上に効果が得られていることを知っ
た0本発明に使用したビール酵母細胞壁は朝日麦酒(株
)の提供の新鮮なビール酵母を、pH10に調整した苛
性ソーダ溶液と50秒接触させ脱苦味したちのを水洗し
、50〜70℃2時間以上放置して完全に自己消化させ
、水に可溶化した成分を水で抽出除去したものであって
その組成は前記した分析値のものであり、この粉末を1
錠243.75.の錠剤としたものである。
(Left below) General components of beer yeast cell wall fraction (analysis example) Loss on drying
10.9% ignition residue
1.5% Total nitrogen 4.0% Crude protein (N x 6.25) 25.0% Thiamine salt 10 μg/g > Riboflavin
10 μg/g > total phosphorus 0
.. 4% Total reducing sugar 49.5%・Glycogen 2469%・Glucan
14.8%*Umbrella Mannan 1
3.9% Kasakafumi glycose equivalent (by Somogyi method after hydrochloric acid digestion) - By Anthrone method after separation After studying the effects on blood insulin and lipids, we found that the effect was greater than expected.The beer yeast cell wall used in the present invention was fresh beer yeast provided by Asahi Beer Co., Ltd. The bitterness was removed by contacting with a caustic soda solution adjusted to The composition of the powder is based on the analysis value described above, and the powder is
Lock 243.75. It is made into tablets.

この錠剤の組成は前記の通りのもので、ビタミン、ミネ
ラルに富むと共にその25%を占める粗蛋白質、グルカ
ン、マンナン等が前述したように50.4%を占める植
物繊維を構成していると考えられ、1日30錠のこの錠
剤の服用は食物繊維3.5gを摂取したことになる。こ
のような前提の基に1型糖尿病2例、2型糖尿病6例に
対しこの錠剤1日30錠ずつを2週間から1ケ月間投与
し1食前食後のGTT、HbA、血中IR工、CPR1
血清コレステロール、中性脂肪について検討するための
臨床実験を行なった。この際のビール酵母細胞壁錠剤の
投与効果は次表の通りであった。
The composition of this tablet is as described above, and it is thought that it is rich in vitamins and minerals, and crude protein, glucan, mannan, etc., which account for 25% of the tablet, constitute vegetable fiber, which accounts for 50.4% as mentioned above. Therefore, if you take 30 tablets a day, you will be ingesting 3.5g of dietary fiber. Based on this premise, 30 tablets per day were administered to 2 patients with type 1 diabetes and 6 patients with type 2 diabetes for 2 weeks to 1 month, and GTT, HbA, blood IR concentration, and CPR1 were administered before and after meals.
A clinical experiment was conducted to examine serum cholesterol and triglyceride levels. The effects of administering the beer yeast cell wall tablets at this time were as shown in the table below.

ビール酵母壁錠剤の糖尿病患者に対する効果前表から8
例中5例にGTTの改善が認められHbA値の低下など
腎機能のコントロールの改善が求められた。インスリン
治療中の2例については、1例ではインスリンが不用と
なり他の1例ではインスリンの使用量が半減した。
Effect of beer yeast wall tablets on diabetic patients 8 from the previous table
Improvement in GTT was observed in 5 of the cases, and improvement in renal function control, such as a reduction in HbA levels, was required. Of the two patients undergoing insulin treatment, one case no longer required insulin, and the other case's insulin usage was halved.

血中IRI値については血糖減少と共に4例においてI
RI値が抑制された。しかしGTT改善時のインスリン
の分泌が増化した例もあった。血中脂質に対しては2例
においてコレステロール、中性脂肪の抑制を示した。こ
の効果を次表の43才の男性患者についての治療結果に
より示す。
Regarding blood IRI values, in 4 cases I
RI value was suppressed. However, there were also cases where insulin secretion increased when GTT improved. Regarding blood lipids, two cases showed suppression of cholesterol and neutral fat. This effect is illustrated by the treatment results for a 43 year old male patient in the following table.

本発明による錠剤の薬効 身長     169am 体重  投与前 77kg 投与後 77kg 血糖日内変動 血中脂質 以上に述べた臨床例において1日30錠のビール酵母錠
剤の摂取は食物繊維約3.5gを食事以外に摂取したこ
とになる。しかし前記した8例の患者からは服用後の腹
部の膨満感、ガス発生の訴えは特にみられなかった。更
に本発明の錠剤の投与により糖尿病に供う高脂血症の改
善が認められた。
Medicinal efficacy of tablets according to the present invention Height: 169 am Weight: Before administration: 77 kg After administration: 77 kg Blood sugar diurnal fluctuations Blood lipids In the clinical example described above, ingestion of 30 brewer's yeast tablets per day means intake of about 3.5 g of dietary fiber in addition to meals. That means you did it. However, none of the eight patients mentioned above complained of abdominal fullness or gas generation after taking the drug. Furthermore, improvement in hyperlipidemia associated with diabetes was observed by administration of the tablets of the present invention.

Claims (1)

【特許請求の範囲】[Claims] 1、ビール酵母細胞壁成分を主成分とする糖尿病コント
ロール剤。
1. Diabetes control agent whose main ingredient is beer yeast cell wall component.
JP60010264A 1985-01-22 1985-01-22 Diabetes-controlling agent Pending JPS61167622A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP60010264A JPS61167622A (en) 1985-01-22 1985-01-22 Diabetes-controlling agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60010264A JPS61167622A (en) 1985-01-22 1985-01-22 Diabetes-controlling agent

Publications (1)

Publication Number Publication Date
JPS61167622A true JPS61167622A (en) 1986-07-29

Family

ID=11745451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60010264A Pending JPS61167622A (en) 1985-01-22 1985-01-22 Diabetes-controlling agent

Country Status (1)

Country Link
JP (1) JPS61167622A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001055338A (en) * 1999-08-13 2001-02-27 Kirin Brewery Co Ltd Pharmacological composition comprising yeast cell wall fraction
JP2005120100A (en) * 2004-10-29 2005-05-12 Kirin Brewery Co Ltd Prophylaxis and/or symptom ameliorate agent for allergic disease comprising yeast cell wall fraction
JP2006117566A (en) * 2004-10-20 2006-05-11 Asahi Breweries Ltd Saccharometabolism-ameliorating agent
JP2007501829A (en) * 2003-08-11 2007-02-01 ルサフル、エ、コンパニ Yeast cell wall used to treat or prevent hyperglycemia or stabilize blood sugar
JP2007045714A (en) * 2005-08-05 2007-02-22 Kirin Brewery Co Ltd Composition for ameliorating skin condition
JP2007519620A (en) * 2003-12-05 2007-07-19 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Antidiarrheal composition containing glutamine
JP2007217435A (en) * 2007-06-01 2007-08-30 Kirin Holdings Co Ltd Agent for prevention and/or amelioration of constipation composed of yeast cell wall fraction
WO2009013357A1 (en) * 2007-07-25 2009-01-29 Lesaffre Et Compagnie Use of yeast flakes for treating and/or preventing hyperinsulinemia
JP2009261362A (en) * 2008-04-28 2009-11-12 Kirin Food-Tech Co Ltd Method for preparing glycogen from yeast
JP2013512197A (en) * 2009-11-25 2013-04-11 王立平 Compound microorganism preparation for the treatment of diabetes, its production method and use

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001055338A (en) * 1999-08-13 2001-02-27 Kirin Brewery Co Ltd Pharmacological composition comprising yeast cell wall fraction
JP2007501829A (en) * 2003-08-11 2007-02-01 ルサフル、エ、コンパニ Yeast cell wall used to treat or prevent hyperglycemia or stabilize blood sugar
JP4808619B2 (en) * 2003-08-11 2011-11-02 ルサフル、エ、コンパニ Yeast cell wall used to treat or prevent hyperglycemia or stabilize blood sugar
JP2007519620A (en) * 2003-12-05 2007-07-19 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Antidiarrheal composition containing glutamine
JP2006117566A (en) * 2004-10-20 2006-05-11 Asahi Breweries Ltd Saccharometabolism-ameliorating agent
JP2005120100A (en) * 2004-10-29 2005-05-12 Kirin Brewery Co Ltd Prophylaxis and/or symptom ameliorate agent for allergic disease comprising yeast cell wall fraction
JP4545063B2 (en) * 2005-08-05 2010-09-15 キリンホールディングス株式会社 Skin condition improving composition
JP2007045714A (en) * 2005-08-05 2007-02-22 Kirin Brewery Co Ltd Composition for ameliorating skin condition
JP2007217435A (en) * 2007-06-01 2007-08-30 Kirin Holdings Co Ltd Agent for prevention and/or amelioration of constipation composed of yeast cell wall fraction
FR2919187A1 (en) * 2007-07-25 2009-01-30 Lesaffre Et Cie Sa USE OF YEAST SKIN FOR THE TREATMENT AND / OR PREVENTION OF HYPERINSULINEMIA.
WO2009013357A1 (en) * 2007-07-25 2009-01-29 Lesaffre Et Compagnie Use of yeast flakes for treating and/or preventing hyperinsulinemia
US9750762B2 (en) 2007-07-25 2017-09-05 Lesaffre Et Compagnie Use of yeast flakes for treating and/or preventing hyperinsulinemia
JP2009261362A (en) * 2008-04-28 2009-11-12 Kirin Food-Tech Co Ltd Method for preparing glycogen from yeast
JP2013512197A (en) * 2009-11-25 2013-04-11 王立平 Compound microorganism preparation for the treatment of diabetes, its production method and use

Similar Documents

Publication Publication Date Title
Canal et al. A chloroform extract obtained from a decoction of Ficus carica leaves improves the cholesterolaemic status of rats with streptootocin-includede diabetes
KR100450645B1 (en) Enzymatic lysate of laver and uses thereof
CN111035649B (en) NMN + GLP compound nutritional supplement and preparation method and application thereof
JPS61167622A (en) Diabetes-controlling agent
CA2429117C (en) Remedy for diabetes mellitus
JP2006519867A (en) Therapeutic composition
JPH0678235B2 (en) Gastrointestinal mucosal tissue disorder therapeutic agent
AU2004267928B2 (en) Yeast cell walls for the treatment or prevention of hyperglycemia or for the stabilisation of glycemia
JP2002051735A (en) Food product composition
US5491150A (en) Supplementary therpeutic agents for the treatment of immunodeficiency syndrome
JP2001103928A (en) Food composition
CN108771246B (en) Composition for improving immunity and restoring physiological function of patients after operation or chemotherapy
KR100483328B1 (en) Composition for Promotion of Fatigue Recovery And Process for Preparation Thereof, Medicine of Fatigue Recovery Using The Same
JPH1077232A (en) Preventive and therapeutic agent for complication by diabetic
CN106620012A (en) Green plum enzyme nutrient liquid and preparation method thereof
KR20130041494A (en) The composition for treating diabetes
CN106822338A (en) Compound of reducing blood sugar and blood fat, prevention and/or treatment diabetes and its complication and application thereof
CN113521262A (en) Lysozyme preparation with anti-inflammatory effect
JP3832871B2 (en) Lipase inhibitor
AU2005242204B2 (en) Remedies for diabetes mellitus
JP2002255832A (en) Mineral absorption-promoting agent and anemia- improving agent
JP2003212775A (en) Physiologically active composition
JPH09143085A (en) Hepatotonic agent containing licorice component
Bach et al. Rheumatic fever
JP5080709B2 (en) Antihyperlipidemic composition and method for producing the same